For instance, studies have shown an upregulation of IGFBP2 in breast and cervical cancers [58, 59, 60], while downregulation has been noted in glioma, bladder cancer, and rhabdomyosarcoma (RMS) [61, 62, 63]. This evidence concerns the gene IGFBP2 and central nervous system cancer.